Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: infliximab

4 Rheumatoid Arthritis Therapy Principles, & New Drug Info

Thomas R. Collins  |  July 19, 2018

CHICAGO—Amid what she called a “dizzying array of choices” for rheumatoid arthritis (RA)—from anti-TNF and anti-IL6-receptor therapies to B cell depletion to new biosimilar options—disease treatment should still revolve around several basic concepts, an expert said at the ACR State-of-the-Art Clinical Symposium in April. Joan Bathon, MD, chief of rheumatology at Columbia University in New…

Filed under:ConditionsRheumatoid Arthritis Tagged with:2018 State of the Art Clinical SymposiumBiosimilarsDisease-modifying antirheumatic drugs (DMARDs)ILDInterstitial Lung Disease

Prenatal TNF Inhibitor Exposure Not Linked to Serious Infections

Anne Harding  |  May 29, 2018

NEW YORK (Reuters Health)—Children of women with rheumatoid arthritis (RA) who are exposed to tumor necrosis factor-alpha inhibitors (TNFis) in the womb are not at markedly increased risk of serious infections, new findings suggest. “It’s reassuring for mothers who need to take these medications during pregnancy,” Evelyne Vinet, MD, of McGill University Health Center in…

Filed under:Drug Updates Tagged with:infantspregnancyRheumatoid Arthritis (RA)tumor necrosis factor (TNF) inhibitors

Rheumatology Coding Corner Answer: Billing for an Inflectra Infusion

From the College  |  May 17, 2018

Take the challenge. CPT codes: 96413, 96415, 96375, Q5103x20, J1200 ICD-10: M07.9 Coding Rationale This procedure is billed with CPT code 96413 for the initial hour of the intravenous infusion and CPT code 96415 for each additional hour. The patient was given 50 mg of diphenhydramine prior to the infusion to prevent reactions and should…

Filed under:Billing/CodingFrom the CollegePractice Support Tagged with:Billing & CodingINFLECTRA (infliximab-dyyb)

Rheumatology Coding Corner Question: Billing for an Inflectra Infusion

From the College  |  May 17, 2018

A 68-year-old female patient returns to the office for a second round of Inflectra (infliximab-dyyb) infusion for her rheumatoid arthritis with rheumatoid factor of multiple joints without organ or systems involvement. She reports pain, stiffness and swelling in her left and right knees and right elbow and rates the pain at a 9 on a…

Filed under:Billing/CodingFrom the CollegePractice Support Tagged with:Billing & CodingINFLECTRA (infliximab-dyyb)

Rheumatology Coding Corner Answer: RA Follow-Up with Imaging

From the College  |  April 26, 2018

Take the challenge. CPT codes: 99214, 71045, 86580 ICD-10: M05.79, R05, R06.2 History—Detailed: The history of present illness (HPI) was extended; the review of systems (ROS) was extended; and the past medical, family and social history (PFSH) were documented. All three components of the HPI, ROS and PFSH are needed to achieve the detailed history…

Filed under:Billing/CodingFrom the CollegePractice Support Tagged with:Billing & CodingRheumatoid arthritis

Rheumatology Coding Corner Question: RA Follow-Up with Imaging

From the College  |  April 26, 2018

History A 39-year-old woman returns for follow-up for her rheumatoid arthritis. She has positive rheumatoid factor, but no organ or systemic involvement. She has joint swelling and pain in her left hand, right elbow and right knee. Her pain is at an 8 on a 10-point scale. She states the pain is worse in the…

Filed under:Billing/CodingFrom the CollegePractice Support Tagged with:Billing & CodingRheumatoid arthritis

Can Certain DMARDs Treat Dementia?

Larry Beresford  |  April 26, 2018

In the complex web of interactions between systemic inflammatory response, rheumatic disease and disease-modifying anti-rheumatic drugs (DMARDs), what is the potential for using rheumatologic therapies to treat other medical conditions linked to inflammation? Some medical researchers have looked at cardiac conditions, and others have examined the overlap with Alzheimer’s disease and other dementias. Positive effects…

Filed under:Uncategorized Tagged with:Alzheimer's DiseasedementiaDisease-modifying antirheumatic drugs (DMARDs)

Baricitinib Appears Effective in Biologic-Refractory RA

Reuters Staff  |  March 27, 2018

NEW YORK (Reuters Health)—The selective Janus kinase 1 and 2 inhibitor baricitinib appears also to help patients whose rheumatoid arthritis (RA) has not responded adequately to biologic disease-modifying antirheumatic drugs, according to results from the RA-BEACON randomized trial. The previously published overall results from RA-BEACON showed that baricitinib-treated patients had significantly better functional and clinical…

Filed under:ConditionsRheumatoid Arthritis Tagged with:baricitinibbiologic-refractory RA

Dealing with Simultaneous Cancer & Rheumatic Disease

Thomas R. Collins  |  March 17, 2018

SAN DIEGO—New insights into how scleroderma and myositis may be linked with cancer have led to intriguing questions that could impact patient care, experts said at the 2017 ACR/ARHP Annual Meeting in November. Understanding the relationship between cancer and rheumatic diseases is important because rheumatologists are seeing more and more patients with both diseases, and…

Filed under:Meeting ReportsSystemic Sclerosis Tagged with:ACR/ARHP Annual Meeting

Periodontitis May Provide Insight into RA

Lara C. Pullen, PhD  |  March 12, 2018

Researchers explored the role of carbamylated protein (CarP) and neutrophil extracellular traps (NETs) in periodontitis and rheumatoid arthritis (RA). The results showed significantly higher levels of CarP and NETs in patients with both RA and periodontitis than in healthy controls. The data suggest that RA and periodontitis may share an underlying pathogenic mechanism…

Filed under:ConditionsRheumatoid Arthritis Tagged with:carbamylated proteinneutrophil extracellular trapsperiodontitisRheumatoid Arthritis (RA)

  • « Previous Page
  • 1
  • …
  • 16
  • 17
  • 18
  • 19
  • 20
  • …
  • 41
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences